Dr. Mary Claire Haver: HRT Guide for Menopause Treatment

Feb 19, 2025

Hormone Replacement Options and Treatments for Menopause

Understanding hormone replacement therapy (HRT) during menopause requires clarity around the specific hormones involved and their delivery methods. The medical community has largely settled on using estradiol as the primary form of estrogen replacement, attempting to mirror what the body naturally produced before menopause.

When it comes to hormone delivery, local treatments often prove both effective and safer than systemic options. Vaginal estrogen, for instance, doesn’t typically result in significant systemic absorption, making it a viable option even for patients with complicated medical histories.

The timing of intervention matters significantly. The traditional approach of waiting until symptoms appear before beginning vaginal estrogen treatment is being reconsidered. Given that all women will eventually experience genital urinary syndrome of menopause (GSM), earlier intervention could prevent numerous complications, including recurrent UTIs and potential hospitalizations.

Testosterone, while not FDA-approved for women in the US, shows promising results for multiple conditions. Women with higher testosterone levels demonstrate better bone density and stronger muscles. Additionally, many patients report improved cognitive function and sleep quality with testosterone supplementation.

Local hormone treatments can target specific concerns effectively. For instance, facial applications of estriol can help address the dramatic 30% collagen loss that occurs in the first five years of menopause. Similarly, vaginal DHEA preparations like Intrarosa can improve local tissue health by converting to both testosterone and estradiol at the site of application.

Hormone therapy spans beyond just estrogen replacement. The process involves careful consideration of various hormones, including:
– Estrogens
– Androgens
– Progesterone
– DHEA

Understanding the interplay between these hormones is crucial. For example, estrogen replacement can affect thyroid hormone levels, necessitating careful monitoring and adjustment of thyroid medication in patients receiving both treatments.

The evolution of hormone therapy has been complicated by confusing terminology and misconceptions. Terms like “estrogen dominance” have emerged from well-meaning providers but lack scientific backing in medical literature. This highlights the importance of adhering to evidence-based terminology and treatment protocols.

For urinary health specifically, vaginal estrogen can significantly improve both urge incontinence and bladder inflammation. While stress incontinence remains primarily an anatomical issue, improved tissue health through hormone therapy can complement other treatments like physical therapy.

Estrogen Benefits and Menopause Treatment

The misconceptions surrounding estrogen therapy and women’s health care have created a troubling gap in medical treatment. Despite strong evidence supporting estrogen’s neuroprotective properties and its role in preventing various health conditions, many healthcare providers remain hesitant to prescribe hormone replacement therapy (HRT).

Haver points out a stark reality: only 10% of women experiencing menopausal symptoms are offered any therapy, and they’re four times more likely to receive an antidepressant than HRT. This approach overlooks the fundamental metabolic changes that occur during menopause, including increased risks of cardiovascular disease, diabetes, insulin resistance, and cholesterol problems.

The historical perspective on estrogen has been largely misunderstood. Contrary to popular belief, estrogen itself is not carcinogenic. Huberman notes that pregnancy, a state of elevated estrogen, doesn’t increase breast cancer risk. In fact, pregnancy before age 40 may protect against certain forms of breast cancer.

The current medical education system fails to adequately address women’s health beyond reproductive concerns. This oversight has serious consequences. Women experience cardiovascular symptoms differently than men, leading to longer emergency department wait times and higher mortality rates from heart attacks. The standard of care often relies on treatments tested primarily on male subjects, despite clear evidence of gender-specific responses to medications and diseases.

Consider the widespread prescription of statins for menopausal women with elevated cholesterol. According to the American Heart Association’s 2020 publication, statins have never been shown to decrease primary heart attacks in women or reduce their cardiovascular mortality risk. However, HRT, when administered within the appropriate window of opportunity, does demonstrate these protective effects.

The administration of HRT has evolved to prioritize safety. While oral formulations are available, non-oral options like patches, sprays, gels, and vaginal rings bypass the liver’s first-pass metabolism, reducing the risk of elevated clotting factors. This approach particularly benefits patients with personal or family histories of blood clots.

A movement of healthcare professionals across specialties, dubbed the “menopausy” by Haver, is working to reshape the narrative around menopause treatment. Their collaborative efforts aim to ensure that women receive comprehensive, evidence-based care that acknowledges their unique physiological needs and responses to treatment.

Monitoring Hormone Therapy Benefits and Levels

In the realm of hormone therapy and menopause care, we’re witnessing a significant shift in understanding and treatment approaches. The traditional view of hormone management is evolving, particularly regarding how we monitor and optimize hormone levels in women experiencing perimenopause and menopause.

Haver emphasizes that hormone therapy isn’t simply about reaching predetermined numbers. Unlike glucose monitoring, which provides clear numerical targets, estrogen therapy requires a more nuanced approach. What works perfectly for one patient might be insufficient for another, even at identical blood levels.

This personalized approach mirrors recent developments in testosterone therapy, where treatment isn’t strictly limited to those with clinically low levels. Instead, practitioners are increasingly focusing on optimizing well-being and managing symptoms rather than adhering to rigid numerical boundaries.

The monitoring of hormone levels varies by type. Testosterone levels in women require more frequent checking due to variable absorption rates and the lack of FDA-approved options. The target range for women typically falls between 35-70 nanograms per deciliter, with levels above 90 warranting investigation for underlying conditions.

A fascinating aspect of hormone biology that challenges conventional wisdom is that women naturally have higher absolute levels of testosterone than estrogen, and men maintain higher baseline estradiol levels than post-menopausal women due to aromatization of testosterone. This understanding dismantles the oversimplified notion of “male” and “female” hormones – they are, in fact, human hormones present in both sexes in varying amounts.

The future of hormone therapy monitoring looks promising. Just as continuous glucose monitors have revolutionized diabetes management, Haver envisions similar technology for tracking estrogen levels. This could enable earlier detection of hormonal changes and more proactive management of perimenopause.

More research is needed to establish optimal therapeutic ranges for various health outcomes. Current studies have primarily focused on whether patients receive hormone therapy or not, rather than identifying ideal dosages for specific benefits such as cardiovascular health or cholesterol management.

The field requires a shift from reactive to proactive care. Starting hormone monitoring in women’s 30s could provide valuable insights into cycle variations and guide earlier interventions. This approach could transform how we manage the transition through perimenopause and beyond.

HRT Contraindications and Treatment Effects

Hormone Replacement Therapy (HRT) stands as a powerful intervention for menopausal women, yet its full spectrum of benefits extends beyond the commonly discussed symptoms. Haver’s clinical experience, combined with Huberman’s scientific inquiry, reveals compelling insights about HRT’s impact on age-related sensory decline.

The anti-inflammatory properties of estrogen play a crucial role in maintaining eye health. While dry eye might seem trivial, it represents a multi-billion dollar concern affecting countless women. HRT has demonstrated effectiveness in reducing its incidence and severity. The therapy’s influence extends to other sensory systems, particularly affecting vestibular function.

Menopause accelerates the displacement of ear crystals, leading to increased vertigo symptoms. Women using HRT experience significantly fewer episodes of new-onset vertigo. Similarly, the decline in estrogen levels correlates with increased tinnitus, though the exact mechanisms require further research.

Beyond sensory improvements, HRT shows promising results for musculoskeletal conditions. Frozen shoulder, a particularly debilitating condition, presents a shorter duration and more manageable course in women receiving hormone therapy.

However, HRT isn’t suitable for everyone. Contraindications include hormone-sensitive cancers and active blood clots. Unexplained dysfunctional uterine bleeding requires thorough evaluation before initiating therapy. Severe liver disease also presents a contraindication, though mild fatty liver disease often improves with HRT.

A common misconception surrounds breast cancer survivors. Previous hormone-sensitive cancer doesn’t automatically disqualify someone from future HRT. The decision requires nuanced consideration of cancer type, stage, and individual circumstances.

The transformative potential of HRT in addressing chronic pain and improving quality of life remains significant. As Haver emphasizes, many of these challenging symptoms are preventable through intentional and aggressive treatment approaches, with HRT serving as a cornerstone of comprehensive care.

Starting HRT After Age 60

The question of starting hormone replacement therapy (HRT) after age 60 remains a critical yet often misunderstood medical decision. While the optimal window for initiating HRT occurs within the first decade of menopause, later adoption isn’t necessarily contraindicated.

Haver emphasizes that women beyond the 10-year post-menopausal window or over 60 require careful evaluation before starting HRT. The assessment focuses primarily on cardiovascular risk factors, including blood pressure, lipid panels, and cholesterol levels. For higher-risk patients, additional screening such as calcium cardiac scoring or carotid ultrasounds may be necessary to evaluate arterial health and atherosclerotic disease progression.

Though these women may have missed the prime window for cardiovascular benefits, HRT continues to offer significant advantages. The therapy provides ongoing protection for bone density, the genitourinary system, and skin health. These benefits persist regardless of when treatment begins, making it a viable option for properly screened candidates.

The antiquated practice of arbitrary treatment duration limits has given way to a more individualized approach. Women who begin HRT early in menopause and maintain good health can potentially continue treatment indefinitely, provided they don’t develop contraindications. As Haver notes, the protective effects of estrogen extend across multiple biological systems, making long-term therapy both reasonable and beneficial for many women.

Huberman draws a parallel between estrogen replacement in women and testosterone replacement therapy, highlighting the evolving understanding of hormone optimization across genders. This comparison underscores the broader shift in medical thinking about hormone replacement – from a time-limited intervention to a potential lifetime therapeutic approach for eligible patients.

Hormone Therapy Side Effects and Alternatives

Hormone replacement therapy (HRT) remains a crucial intervention for managing menopausal symptoms, but understanding its nuances and alternatives is essential for making informed healthcare decisions.

Cost considerations often influence treatment choices. While testosterone treatments can be relatively affordable at around $30 monthly in certain regions like Texas, medications such as vylecine and addi tend to be more expensive and frequently aren’t covered by insurance plans.

When it comes to estradiol-based HRT, some patients experience adverse reactions, particularly skin issues like rashes and hives. However, Haver notes that these reactions often stem from the adhesive in patches rather than the hormone itself. A practical solution involves applying over-the-counter Flonase nasal spray to the skin before patch application, which can reduce adhesive reactions. Alternatively, switching to different delivery methods of estradiol might resolve these issues.

The supplement market offers various alternatives, including Equell and wild yam products. However, Haver cautions about the limited scientific evidence supporting their efficacy. While most of these supplements are generally harmless, they may not address the root cause of menopausal symptoms. The most effective approach typically involves properly restoring estradiol levels.

Alternative therapies like acupuncture can provide symptom relief, but accessibility and cost remain significant barriers. Moreover, while these treatments may help manage symptoms, they don’t address the underlying hormonal changes.

Addressing body fat distribution during menopause requires a comprehensive strategy. This includes:
– Proper nutrition
– Regular exercise
– Hormone replacement therapy (which has been shown to reduce visceral fat)
– Stress management to regulate cortisol levels

The key to successfully navigating perimenopause and menopause lies in adopting this multifaceted approach. By combining appropriate medical interventions with lifestyle modifications, women can maintain better control over their health during these transitional periods. Rather than viewing these phases as inevitable decline, they can be approached with agency and practical solutions.

Read Andrew Huberman

Discussion about this post